Download the app
App StorePlay Store
Beige
Login
← All tags

pharma

Zydus Lifesciences shares jump 6% as May 19 buyback plan and 166 million Assertio deal surface

Zydus Lifesciences shares jump 6% as May 19 buyback plan and 166 million Assertio deal surface

Zydus Lifesciences shares surged nearly 6% after the company said its board will meet on May 19 to consider a share buyback. The rally also drew steam from its plan to acquire US-based Assertio in a deal valued at about $166 million. Investors cheered the mix of potential capital return and growth through strategic expansion.

Summarised by Beize from a story on The Economic Times on 14 May 2026
Markets choppy as foreign outflows rise Pashupati Advani warns investors what to prioritize now

Markets choppy as foreign outflows rise Pashupati Advani warns investors what to prioritize now

Indian markets are staying volatile as inflation pressure and supply chain issues build toward an impending slowdown. Foreign investors are trimming exposure, adding to the turbulence. Pashupati Advani of Global Foray says investors should stay cautious, focus on strong fundamentals, and look selectively at themes like infrastructure, exporters, and pharma aligned with government spending priorities.

Summarised by Beize from a story on The Economic Times on 14 May 2026

Your news, in seconds

App StorePlay Store
Cipla Q4 profit plunges 55 percent YoY to Rs 555 crore but dividend stays on track

Cipla Q4 profit plunges 55 percent YoY to Rs 555 crore but dividend stays on track

Cipla Ltd reported a steep 55% year-on-year fall in consolidated net profit for Q4, dropping to Rs 555 crore from Rs 1,222 crore a year earlier. Despite the decline, the board recommended a final dividend of Rs 13 per share for the fiscal year ending March 2026, signaling continued shareholder payout plans.

Summarised by Beize from a story on The Economic Times on 13 May 2026
SwishX launches agentic AI platform for pharma and medtech to automate tenders pricing and proposals

SwishX launches agentic AI platform for pharma and medtech to automate tenders pricing and proposals

Bengaluru startup SwishX, backed by $2.2 million seed funding, has launched what it calls the world’s first agentic AI platform built for pharma and medtech companies. The system targets faster sales, marketing and distribution outcomes, including AI evaluation of thousands of tenders, analysis of 500+ page documents, and proposal drafting in minutes—aiming to cut decision and execution delays by up to 30%.

Summarised by Beize from a story on IndianWeb2 on 12 May 2026
US moves psychedelics into research mode, and India’s pharma opportunity just widened

US moves psychedelics into research mode, and India’s pharma opportunity just widened

The US is rapidly accelerating research into psychedelics for mental illness, signaling a major shift from counterculture to mainstream R&D. That change should push India to revisit its drug policies and build the ecosystem needed for responsible progress. With deep cultural ties to altered states, India can lead by funding research centers, developing therapies, and modernizing legal frameworks.

Summarised by Beize from a story on The Economic Times on 8 May 2026
Biocon turns to margins and capacity use after heavy global expansion investments

Biocon turns to margins and capacity use after heavy global expansion investments

Biocon says it is moving from an expansion phase to a focus on capacity utilization, margin expansion, and stronger returns. After major investments to build global capabilities, the company reported 13% revenue growth for FY26, but net profit fell significantly. Biocon is also aiming for sustainable profitable growth while exploring in-licensing for its biosimilars portfolio.

Summarised by Beize from a story on The Economic Times on 8 May 2026

Never miss a story

App StorePlay Store
Torrent wins 38 percent share as semaglutide generics surge across India

Torrent wins 38 percent share as semaglutide generics surge across India

After Novo Nordisk’s innovator semaglutide patent expired in end-March, over a dozen Indian firms launched generics. In April, these generics sold about ₹44 crore in total, with Torrent emerging as the fastest mover, grabbing around 38% market share. The sprint signals intensifying competition in GLP-1 diabetes and weight-management drugs.

Summarised by Beize from a story on The Economic Times on 7 May 2026
Zydus Biologics Ahmedabad facility faces seven USFDA observations but data integrity stays clean

Zydus Biologics Ahmedabad facility faces seven USFDA observations but data integrity stays clean

Zydus Lifesciences says its Zydus Biologics injectable plant in Ahmedabad was inspected by the USFDA from April 27 to May 5, 2026. The audit resulted in seven observations, though the company emphasized that there were no data integrity issues. Zydus is now in discussions with the USFDA to address the findings promptly and maintain compliance.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Sun Pharma jumps into global top 25 as it buys Organon for 11.75 billion

Sun Pharma jumps into global top 25 as it buys Organon for 11.75 billion

Sun Pharma’s acquisition of Organon in a record $11.75 billion deal propels the company into the world’s top 25 pharma players. While chairman Dilip Shanghvi is excited by the leap in scale and ambition, the moment also carries anxiety—highlighting how even “winning” mergers demand careful execution.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Indian firms pour 16.4 billion into US creating 70800 jobs and funding R and D

Indian firms pour 16.4 billion into US creating 70800 jobs and funding R and D

Indian companies have invested USD 16.4 billion in the United States, helping create about 70,800 jobs, according to officials. The firms also put USD 330 million toward research and development, backing innovation alongside community growth across multiple states. The inflow is being framed as a boost to the US economy, with companies like Sun Pharmaceutical recently announcing major deals.

Summarised by Beize from a story on The Economic Times on 5 May 2026

Reading on mobile?

App StorePlay Store
Wockhardt shares surge 9% as biotech turnaround lifts profit and FY26 growth outlook

Wockhardt shares surge 9% as biotech turnaround lifts profit and FY26 growth outlook

Wockhardt shares jumped around 9% after the pharma firm reported a strong March-quarter turnaround. Net profit returned to positive territory as revenue rose sharply, and full-year earnings improved too. Biotech operations drove much of the momentum, supported by expansion across emerging markets. The company also said its pipeline grew through new filings and approvals.

Summarised by Beize from a story on The Economic Times on 5 May 2026
Pharma exports top 31 billion in FY26 as US and China slump drives chaos

Pharma exports top 31 billion in FY26 as US and China slump drives chaos

Indian pharmaceutical exports crossed $31 billion in FY26 despite global headwinds. But March deliveries fell 23%, largely linked to weaker demand from the United States and China. Growth held up in markets such as Africa and Oceania, and vaccines led the fastest expansion, signaling a shift in where India’s drug makers are finding momentum.

Summarised by Beize from a story on The Economic Times on 4 May 2026
Indian pharma Q4 outlook mixed as Revlimid drag hits generics and hospitals stay steady

Indian pharma Q4 outlook mixed as Revlimid drag hits generics and hospitals stay steady

Indian pharma and healthcare companies are entering a mixed March quarter. Hospital networks expect steady growth, supported by demand across segments. But generic drugmakers are wrestling with lost Revlimid sales and pricing pressures that weigh on performance. Analysts see pockets of strength: Lupin and Divi’s look set to do well, while Sun Pharma and Torrent show resilience. Apollo Hospitals projects strong overall traction.

Summarised by Beize from a story on The Economic Times on 4 May 2026
Bombay HC supports GSK in Paxil trademark fight over alleged decades of non use

Bombay HC supports GSK in Paxil trademark fight over alleged decades of non use

The Bombay High Court backed GSK’s Indian unit in its Paxil trademark dispute with Shreya Life Sciences. GSK argued that while Shreya secured the mark more than two decades ago, it never used it for pharmaceutical and medicinal preparations. That, GSK said, makes the registration liable for removal under Section 47 of the Trade Marks Act.

Summarised by Beize from a story on The Economic Times on 2 May 2026

Follow your favourite sources

App StorePlay Store
India says its pharma IP rules are WTO compliant as US pressure mounts over generics

India says its pharma IP rules are WTO compliant as US pressure mounts over generics

India maintains that its intellectual property rules for pharmaceuticals are WTO compliant, even as the United States continues to press for stronger protections. The dispute comes as India supplies about 20% of global generic medicines, putting generics access and the domestic industry at the center of the argument. Both sides remain locked in long-running policy differences.

Summarised by Beize from a story on The Economic Times on 1 May 2026
Quick commerce reshapes Indian medicine buying as acute sales slip and wellness surges

Quick commerce reshapes Indian medicine buying as acute sales slip and wellness surges

India’s pharmacy delivery model is shifting as quick-commerce apps make it simpler to reorder medicines and health products. Overall sales haven’t surged, but demand is moving: wellness items are rising while acute care medicines are declining. With more shoppers turning online for health essentials, the market appears to be changing its mix rather than booming overall.

Summarised by Beize from a story on The Economic Times on 1 May 2026
India pharma exports hit compliance squeeze forcing a new quality led playbook

India pharma exports hit compliance squeeze forcing a new quality led playbook

As global regulators tighten standards, India’s pharma industry is moving beyond its old cost advantage toward tighter compliance, quality systems, and regulatory trust. With scrutiny rising across target markets, exporters face higher expectations on documentation, testing, and manufacturing practices, pushing the $30 billion export engine to recalibrate its playbook for long term access.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026
Nandini Piramal flags West Asia conflict risk that could push up pharma input costs

Nandini Piramal flags West Asia conflict risk that could push up pharma input costs

Nandini Piramal says West Asia tensions are manageable today, but a prolonged US Israel war against Iran could raise costs for petrochemical derived products that feed parts of the pharma supply chain. Piramal Pharma is responding by diversifying sourcing and using global manufacturing. It expects stronger momentum in contract development and manufacturing, with growth from overseas sites and complex hospital generics.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026

Stay informed on the go

App StorePlay Store
Emcure Pharma block deal Rs 289 crore ends as Norges Bank buys 18 lakh shares

Emcure Pharma block deal Rs 289 crore ends as Norges Bank buys 18 lakh shares

Emcure Pharmaceuticals reported a major block deal as BC Investments IV Limited sold about 18 lakh shares worth Rs 289 crore to Norges Bank. The buyer’s entry comes as the pharma company keeps outperforming, posting a 67% return over the past 12 months and a 50% year-on-year jump in net profit, bolstering investor interest.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Cohance Lifesciences shares jump 20% after naming former Cipla CEO Umang Vohra as boss

Cohance Lifesciences shares jump 20% after naming former Cipla CEO Umang Vohra as boss

Cohance Lifesciences shares surged 20% on Monday after appointing former Cipla CEO Umang Vohra as Executive Chairman and Group CEO. The company expects his leadership to push transformation, expand operations, and deepen global partnerships as it moves into a new growth phase. Investors reacted sharply to the change at the top.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play